Literature DB >> 17230409

DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine.

Vladimir N Loparev1, Elena Rubtcova, Jane F Seward, Myron J Levin, D Scott Schmid.   

Abstract

Little is known about the pathogenic potential of individual strains in the varicella vaccine. We analyzed genomic variation among specimens obtained from vaccine recipients with postvaccination rash or herpes zoster (HZ), focusing on polymorphisms between live attenuated varicella vaccine virus and wild-type varicella-zoster virus. Eleven of 18 postvaccination HZ specimens contained >1 strain, and 7 of 18 appeared to be clonal. All 21 postvaccination rash specimens contained mixtures of vaccine strains. Four single-nucleotide polymorphisms (SNPs) consistently occurred in every isolate; all were polymorphisms in open-reading frame (ORF) 62, and 2 confer amino acid substitutions in the immediate-early protein 62. Four wild-type SNPs occurred in every isolate: one each occurred in ORF 10, ORF 21, ORF 62, and a noncoding region upstream of ORF 64. The frequencies of the remaining wild-type SNPs were variable, with the SNPs uniformly expressed (even in mixtures) in 20.5%-97.4% of isolates (mean frequency, 67.7%). No 2 clinical isolates had identical SNP profiles; as such, vaccine latency usually involves >1 strain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17230409     DOI: 10.1086/510532

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster.

Authors:  Mark L Quinlivan; Nancy J Jensen; Kay W Radford; D Scott Schmid
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

2.  Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions.

Authors:  Sonja Thiele; Aljona Borschewski; Judit Küchler; Marc Bieberbach; Sebastian Voigt; Bernhard Ehlers
Journal:  Clin Vaccine Immunol       Date:  2011-05-11

3.  Population diversity in batches of the varicella Oka vaccine.

Authors:  R K Kanda; M L Quinlivan; A A Gershon; R A Nichols; J Breuer
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

4.  Varicella zoster virus DNA at inoculation sites and in saliva after Zostavax immunization.

Authors:  Duane L Pierson; Satish K Mehta; Don Gilden; Randall J Cohrs; Maria A Nagel; D Scott Schmid; Stephen K Tyring
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

Review 5.  Prevention strategies for herpes zoster and post-herpetic neuralgia.

Authors:  Myron J Levin; Anne A Gershon; Robert H Dworkin; Marc Brisson; Lawrence Stanberry
Journal:  J Clin Virol       Date:  2010-05       Impact factor: 3.168

6.  Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand.

Authors:  Vladimir N Loparev; Elena N Rubtcova; Vanda Bostik; Dhwani Govil; Christopher J Birch; Julian D Druce; D Scott Schmid; Margaret C Croxson
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

Review 7.  Impact of varicella vaccine on varicella-zoster virus dynamics.

Authors:  D Scott Schmid; Aisha O Jumaan
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses.

Authors:  Ruth Harbecke; Michael N Oxman; Beth A Arnold; Charlotte Ip; Gary R Johnson; Myron J Levin; Lawrence D Gelb; Kenneth E Schmader; Stephen E Straus; Hui Wang; Peter F Wright; Constance T Pachucki; Anne A Gershon; Robert D Arbeit; Larry E Davis; Michael S Simberkoff; Adriana Weinberg; Heather M Williams; Carol Cheney; Luba Petrukhin; Katalin G Abraham; Alan Shaw; Susan Manoff; Joseph M Antonello; Tina Green; Yue Wang; Charles Tan; Paul M Keller
Journal:  J Med Virol       Date:  2009-07       Impact factor: 2.327

9.  Discriminating between varicella-zoster virus vaccine and wild-type strains by loop-mediated isothermal amplification.

Authors:  Yuki Higashimoto; Masaru Ihira; Akane Ohta; Shigeki Inoue; Chie Usui; Yoshizo Asano; Tetsushi Yoshikawa
Journal:  J Clin Microbiol       Date:  2008-06-11       Impact factor: 5.948

10.  Cytotoxicity of glioblastoma cells mediated ex vivo by varicella-zoster virus-specific T cells.

Authors:  Jennifer Canniff; Andrew M Donson; Nicholas K Foreman; Adriana Weinberg
Journal:  J Neurovirol       Date:  2011-07-27       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.